Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERICA: Self-administration of subcutaneous Elranatamab in patients’ homes
2023-507876-30-00Phase 2Authorised
- Sponsor
- University Hospital Odense
- Start
- Jul 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elranatamab in multiple myeloma (MM), sponsored by University Hospital Odense. Primary endpoints: Feasibility of home self-administration (dose utilization and setting) and Safety of home self-administration (AEs/SAEs during Period 1). Planned start Jul 2024; status: authorised.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-507876-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507876-30-00.